KK
KK3A.F Cytokinetics Incorporated
- Market cap
- EUR 6.97B
- P/E
- -
- P/B
- 60.23x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KK3A.F undervalued?
Graham numberThe Graham number of Cytokinetics Incorporated cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cytokinetics Incorporated fundamental analysis
No fundamental analysis for Cytokinetics Incorporated yet.
Cytokinetics Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cytokinetics Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omec…
Full company profileCytokinetics Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cytokinetics Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 106M | 13.4M | 31.5M | 26.9M | 55.8M | 70.4M | 94.6M | 7.53M | 18.5M | 88.0M | 127M |
| Gross Profit | 42.0M | -76.9M | -57.6M | -59.3M | -41.1M | -89.5M | -146M | -323M | -321M | -328M | 114M |
| Operating Income | 18.7M | -113M | -88.9M | -98.9M | -93.9M | -186M | -324M | -496M | -536M | -612M | -707M |
| EBITDA | - | -109M | -83.5M | -93.0M | -86.8M | -184M | -338M | -457M | -493M | -671M | -637M |
| Net Income | 16.5M | -128M | -106M | -122M | -127M | -215M | -389M | -526M | -590M | -785M | -793M |
| EPS | - | -2.37 | -1.94 | -2.06 | -1.79 | -2.54 | -4.10 | -5.37 | -5.00 | -6.38 | -5.70 |
| Balance Sheet | |||||||||||
| Total Assets | 170M | 295M | 211M | 290M | 534M | 841M | 1.01B | 824M | 1.40B | 1.42B | 1.82B |
| Total Liabilities | 75.8M | 185M | 185M | 301M | 420M | 597M | 1.12B | 1.21B | 1.54B | 2.08B | 2.15B |
| Shareholders' Equity | 94.4M | 110M | 25.9M | -10.9M | 113M | 244M | -108M | -386M | -135M | -660M | -321M |
| Cash & Short-term Investments | 66.9M | 125M | 42.3M | 36.4M | 83.0M | 113M | 65.6M | 113M | 94.9M | 123M | 203M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 37.0M | -102M | -101M | -90.9M | 8.94M | -143M | -300M | -414M | -396M | -510M | -572M |
| Capital Expenditure | 1.60M | 2.88M | 889K | 2.62M | 11.1M | 48.9M | 11.3M | 1.42M | 3.91M | 24.8M | 14.6M |
| Free Cash Flow | - | -105M | -102M | -93.5M | -2.11M | -191M | -311M | -416M | -400M | -535M | -587M |
| Ratios | |||||||||||
| ROE | 17.4% | -116.3% | -409.8% | - | -112.3% | -88.3% | - | - | - | - | - |
| ROA | 9.7% | -43.3% | -50.3% | -42.0% | -23.8% | -25.6% | -38.3% | -63.8% | -42.1% | -55.1% | -43.5% |
| Net Profit Margin | 15.5% | -955.9% | -337.4% | -452.9% | -228.0% | -305.7% | -411.2% | -6,988.6% | -3,191.1% | -891.6% | -622.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cytokinetics Incorporated dividends
Cytokinetics Incorporated has not paid dividends in the last 9 fiscal years.
Last stock split: 1:6 on Jun 25, 2013.
Who owns Cytokinetics Incorporated
- Insiders 0.57%
- Institutions 99.43%
- Public & others 0.00%
- Shares outstanding 139M
- Free float 139M
Cytokinetics Incorporated company profile
- Company name
- Cytokinetics Incorporated
- Ticker
- KK3A.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 673
- Fiscal year end
- December
- Address
- 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 624 3000
- Website
- cytokinetics.com
About Cytokinetics Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics Incorporated management
10- Mr. Robert I. BlumCEO, President & Director · born 1964
- Mr. Sung H. LeeEVP & CFO · born 1970
- Mr. Jeffrey J. Hessekiel J.D.Executive VP, Chief Legal & Administrative Officer · born 1969
- Dr. Fady Ibraham Malik FACC, M.D., Ph.D.Executive Vice President of Research & Development · born 1964
- Mr. Andrew M. CallosExecutive VP & Chief Commercial Officer · born 1969
- Dr. James H. Sabry M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board · born 1958
- Dr. James A. Spudich Ph.D.Co-Founder & Member of Scientific Advisory Board · born 1942
- Ms. Holly LaughlinVP of Accounting & Corporate Controller
- Mr. Steven M. Cook J.D.Senior Vice President of Global Supply Chain Operations & Technical Operations · born 1959
- Mr. Scott R. JordanSenior Vice President of Global Marketing & Commercial Strategy